



## ASX ANNOUNCEMENT

20 June 2007

### VITROGRO<sup>®</sup> GETS POSITIVE NEWS FROM HEALTH CANADA

Biomedical company, Tissue Therapies Limited (ASX: TIS) has confirmed that the classification of the Company's VitroGro<sup>®</sup> received from Health Canada (the Canadian Health Regulatory Body) will accelerate the approval and release of its first wound care products.

CEO, Dr Steven Mercer today confirmed that Health Canada had classified VitroGro<sup>®</sup> as a 'topical biologic' and, accordingly, the clinical regulatory requirements for product assessment would be similar to those required for approval of a medical device, rather than a pharmaceutical.

He said that the classification of VitroGro<sup>®</sup> as a topical biologic meant that the regulatory testing required to bring the Company's products to market would be considerably faster than those required for a pharmaceutical.

"This is an exciting milestone for the commercialisation of VitroGro<sup>®</sup>-based clinical products for wound care and other applications, and a major milestone in the final preparations for the clinical trial scheduled for completion in December 2007," he said.

"The Canadian classification, together with the upcoming clinical trial data, will also provide the opportunity to access the markets of Canada, EU, Switzerland, Australia, New Zealand and Asia, as well as potentially accelerating access into the United States."

Dr Mercer said the Health Canada classification meant that VitroGro<sup>®</sup> clinical products would not be classified as pharmaceuticals and, therefore devices companies would be able to sell and distribute products such as VitroGro<sup>®</sup> wound dressings, facilitating the more rapid market penetration of the Company's wound care products.

"We are currently in discussions with appropriate providers in Canada to undertake the required tests and are very confident that these will be accommodated within the clinical trial timetable," he said.

Dr Mercer said that the GMP manufacturing process was proceeding well and the Company was investigating ways to enhance yields aimed at potentially lowering production costs.

"The Board continues to closely monitor any funding issues that could arise from this enhanced commercialisation pathway, now that the regulatory program is more clearly defined and in view of the more comprehensive clinical trials," he said.

Dr Mercer said that the Health Canada classification of VitroGro<sup>®</sup> clarified the regulatory position for the wound care technology and confirmed the Company's long term view that VitroGro<sup>®</sup> would be regulated like a medical device, rather than a pharmaceutical.

He said that the Company also had recently received independent commercial endorsement of VitroGro® via the worldwide sales and distribution agreement with Invitrogen Corp. and the Joint Development Agreement with Novozymes A/S earlier this year. Both commercial agreements also provide the Company with diversification and access to major global markets for initial VitroGro® products.

## **ENDS**

**For more information:** Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: 07 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## **ADDITIONAL INFORMATION**

### **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)